Initiator Pharma A/S
Stockholm Stock ExchangeTotal Valuation
Initiator Pharma A/S carries a market capitalization of 189.61M, placing it among publicly traded companies globally. Its enterprise value stands at 129.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 189.61M |
| Enterprise Value | 129.09M |
Share Statistics
Initiator Pharma A/S currently has 68.45M shares outstanding.
| Shares Outstanding | 68.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 7.86 |
| P/TBV Ratio | 7.86 |
| P/FCF Ratio | -5.29 |
| P/OCF Ratio | -5.25 |
Financial Position
Initiator Pharma A/S maintains a current ratio of 23.52, meaning it holds 23.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.80, indicating elevated leverage, while an interest coverage ratio of -209.13 demonstrates limited ability to service its debt obligations.
| Current Ratio | 23.52 |
| Quick Ratio | 17.49 |
| Debt / Equity | 41.80 |
| Debt / EBITDA | -0.28 |
| Interest Coverage | -209.13 |
Financial Efficiency
| Return on Equity (ROE) | -149.95 |
| Return on Assets (ROA) | -113.35 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -3.01M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Initiator Pharma A/S's stock has declined approximately -26.5252% over the past 52 weeks. The 50-day moving average sits at 2.95, while the 200-day moving average is 3.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.5252% |
| 50-Day Moving Average | 2.95 |
| 200-Day Moving Average | 3.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -26.56M, while operating income came in at -26.56M.
| Revenue | N/A |
| Gross Profit | -23.91M |
| Operating Income | -26.56M |
| Pretax Income | -25.59M |
| Net Income | -22.58M |
| EBITDA | -26.56M |
| EBIT | -26.56M |
| Earnings Per Share (EPS) | -0.34 |
Balance Sheet
Initiator Pharma A/S holds 19.80M in cash and equivalents against 7.52M in total debt, resulting in a net debt position of -12.28M. Total book value stands at 17.99M, with working capital of 25.50M providing operational flexibility.
| Cash & Cash Equivalents | 19.80M |
| Total Debt | 7.52M |
| Net Debt | -12.28M |
| Equity (Book Value) | 17.99M |
| Book Value Per Share | 0.28 |
| Working Capital | 25.50M |
Cash Flow
Initiator Pharma A/S produced -26.94M in operating cash flow over the past twelve months.
| Operating Cash Flow | -26.94M |
| Capital Expenditures | N/A |
| Free Cash Flow | -26.94M |
| FCF Per Share | -0.41 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -25.44 |
| FCF Yield | -18.92 |
Stock Splits
Initiator Pharma A/S's most recent stock split took place on October 25, 2021 with a 500:537 split ratio.
| Last Split Date | 10/25/2021 |
| Split Ratio | 500:537 |
Scores
Initiator Pharma A/S posts an Altman Z-Score of 8.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.23 |